Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to bone fragility and increased susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.


Bone Mineral Density Measurements
  • Bone mineral density (BMD) measurements give an accurate reflection of bone mass & confirm diagnosis of osteoporosis
  • An excellent predictor of future fracture risk
Methods of Bone Mineral Density Measurement
  • Dual energy X-ray absorptiometry (DXA) of hip & spine
    • Gold standard
    • Diagnose osteoporosis based on bone mineral density (BMD) mesasurement of the hips (conventionally)
    • Monitor therapeutic response based on bone mineral density (BMD)

Bone Mineral Density T-score

WHO Recommended Values* for Diagnosis of Osteoporosis
Bone Mineral Density T-score (SD) Definition
T ≥ -1 Normal
T < -1 to < -2.5 Osteopenia (low bone mass)
T ≤ -2.5 Osteoporosis
T ≤ -2.5 + fracture Severe/established osteoporosis
*Values are based on dual energy X-ray absorptiometry (DXA)
T-score: A comparison with young normal adult mean of the same sex
  • Quantitative CT scan (QCT)
    • Used as an alternative technique when dual energy X-ray absorptiometry (DXA) is not available
    • Measures bone strength in the axial skeleton & volumetric bone density of the vertebra & hip
    • Has higher radiation dose compared to dual energy X-ray absorptiometry (DXA)
  • Trabecular Bone Score (TBS)
    • Evaluates microarchitectural texture of the bone
    • Highly sensitive in predicting fracture risk
Screening Methods (Not for Diagnosis or Monitoring)
  • Peripheral dual-energy X-ray absorptiometry (pDXA)
  • CT-based assessments: Peripheral QCT
  • Quantitative ultrasound densitometry (QUS) of heel, tibia, patella & other peripheral skeletal sites
If fracture is present: Physical exam, lab tests & radiologic tests should also be conducted to exclude underlying diseases that mimic, aggravate or cause osteoporosis eg secondary osteoporosis

Laboratory Tests

  • CBC, erythrocyte sedimentation rate (ESR)
  • Renal function tests
  • Electrolytes (eg ionized calcium [Ca], phosphate, magnesium [Mg])
  • Creatinine, albumin, aspartate aminotransferase (AST), alkaline phosphatase
  • Urinalysis
  • Bone turnover markers
    • Identifies patients at high risk for fractures
    • Used to evaluate efficacy & compliance to current treatment
    • Eg serum C-telopeptide (CTX), osteocalcin, N-terminal propeptide of type 1 procollage (P1NP), tissue transglutaminase antibodies (IgA & IgG), serum protein electrophoresis (SPEP)
  • Others (eg thyroid function as indicated, parathyroid hormone)


  • Scintigraphic bone studies, X-ray of lateral thoraco-lumbar spine or hip (as indicated)
Vertebral Imaging
  • Recommended for the following:
    • Women ≥70 year & men ≥80 year with bone mineral density (BMD) T-score ≤-1.0 at the spine, total hip, or femoral neck
    • Women 65-69 year & men 70-79 year with bone mineral density (BMD) T-score ≤-1.5 at the spine, total hip, or femoral neck
    • Postmenopausal women & men ≥50 year with low trauma fracture during adulthood, historical height loss (current height - peak height at 20 year) by >1.5 inches, prospective height loss (current height - recently documented height) by ≥0.8 inches, &/or currently or previously on long-term glucocorticoid treatment
    • Other bone mineral density (BMD) measurements are unavailable


Indications for Bone Mineral Density (BMD) Measurements
  • All women ≥65 year or women <65 year with ≥1 risk factor for fracture/osteoporosis [recommended by the U.S. National Osteoporosis Foundation (NOF)] or using Osteoporosis Self-Assessment Tool for Asians (OSTA) to assess risk & the need for bone mineral density (BMD) measurement
  • All men >70 year of age, men >50-69 year with risk factors, & men >50 year with history of fracture during adulthood
  • Corticosteroid therapy equivalent to ≥5 mg/day of prednisone for ≥3 month
  • Low body mass index (BMI) (<127 lb or BMI <20 kg/m2), loss of height, thoracic kyphosis
  • Presence of estrogen deficiency (eg prolonged secondary amenorrhea, hypogonadism, premature natural or surgical menopause <45 year, early menopause [<40 year old])
  • Presence of conditions related to osteoporosis (eg hyperparathyroidism, hyperthyroidism, anorexia nervosa, malabsorption, Cushing’s syndrome, prolonged immobilization, rheumatoid arthritis)
  • Radiological evidence of osteopenia or vertebral deformity
  • Women considering treatment for osteoporosis & if bone mineral density (BMD) measurement facilitates decision
  • Postmenopausal women who have had any type of fracture as an adult after age of 50 year
Some authorities recommend that patients >65 year with multiple risk factors or prevalent osteoporotic fracture be started on treatment for osteoporosis without bone mineral density (BMD) measurements

WHO Fracture Risk Assessment Model (FRAXTM)
  • Developed to calculate the 10-year risk of osteoporosis fracture, with or without BMD values, based on individual factors (eg sex, age, ethnicity, family history, previous fracture, glucocorticoid treatment, smoking status, alcohol consumption, rheumatoid arthritis, low BMI)
    • Level of fracture probability will vary between countries
    • Malaysia Osteoporosis Society recommends using the Singaporean prediction algorithm until more Malaysian data are available
  • Useful in identifying among the group of patients with osteopenia those at higher risk of fracture
  • Limitations of FRAXTM include lack of detail on some risk factors (eg smoking, prior fracture, effects of glucocorticoids), non-inclusion of other known risk factors (eg biochemical markers, falls)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Audrey Abella, 20 Jan 2017
Diabetes was not a risk factor for total knee replacement (TKR) due to severe knee osteoarthritis, a Singapore study found.